{"hands_on_practices": [{"introduction": "To truly master pharmacotherapy, we must begin at the molecular level. This first practice delves into the fundamental mechanism of action for stimulant medications, which primarily involves the inhibition of the dopamine transporter (DAT). By applying the principles of Michaelis-Menten kinetics, you will model the DAT as an enzyme and dopamine as its substrate, allowing you to quantitatively predict how a competitive inhibitor alters synaptic dopamine levels. This exercise bridges the gap between abstract biochemical theory and concrete neuropharmacological effects, providing a robust model for understanding how these critical medications work [@problem_id:4739184].", "problem": "A core pharmacotherapeutic mechanism for attention-deficit/hyperactivity disorder (ADHD) is competitive inhibition of the dopamine transporter (DAT), which reduces dopamine clearance without directly altering vesicular release. Consider extracellular dopamine concentration, denoted $[D]$, governed at steady state by a balance between a constant tonic release rate $R$ (assumed independent of $[D]$ over the concentration range considered) and DAT-mediated uptake that follows Michaelis–Menten kinetics, with uptake rate $v = \\dfrac{V_{\\max}[D]}{K_m + [D]}$. At steady state, $R = v$.\n\nIn a striatal microenvironment, suppose that before drug exposure the system is at steady state with parameters $V_{\\max} = 1.0 \\times 10^{3}$ nM/s and $K_m = 200$ nM, and the measured extracellular dopamine concentration is $[D]_0 = 40$ nM. A DAT-selective competitive inhibitor (e.g., methylphenidate) is then administered at a dose that doubles the apparent Michaelis constant without changing the maximal transport capacity, so that $K_m^{\\text{app}} = 2K_m$ while $V_{\\max}$ remains unchanged. Assume the tonic release rate $R$ is unaffected by the drug at this dose and that a new steady state is reached under the same balance equation.\n\nStarting from the steady-state balance and the Michaelis–Menten definition of uptake, compute the change in extracellular dopamine concentration $\\Delta [D] = [D]_1 - [D]_0$ after inhibitor administration. Express your final answer in nM, and round your answer to four significant figures.", "solution": "The user has provided a problem to be solved. As per the instructions, the first step is to validate the problem statement.\n\n### Step 1: Extract Givens\n- **System**: Extracellular dopamine concentration, $[D]$, at steady state.\n- **Governing Equation (General)**: Steady state is achieved when the release rate $R$ equals the uptake rate $v$. Thus, $R = v$.\n- **Uptake Kinetics**: The uptake rate $v$ follows the Michaelis–Menten equation: $v = \\dfrac{V_{\\max}[D]}{K_m + [D]}$.\n- **Initial State (Pre-Inhibitor)**:\n    - A steady state exists, denoted by subscript $0$.\n    - $V_{\\max} = 1.0 \\times 10^{3}$ nM/s.\n    - $K_m = 200$ nM.\n    - Measured extracellular dopamine concentration: $[D]_0 = 40$ nM.\n- **Final State (Post-Inhibitor)**:\n    - A new steady state is reached, denoted by subscript $1$.\n    - The inhibitor is competitive.\n    - The apparent Michaelis constant is $K_m^{\\text{app}} = 2K_m$.\n    - The maximal transport capacity $V_{\\max}$ is unchanged.\n    - The tonic release rate $R$ is unchanged.\n- **Objective**: Compute the change in extracellular dopamine concentration, $\\Delta [D] = [D]_1 - [D]_0$.\n- **Final Answer Requirement**: Express the answer in nM, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientific or Factual Soundness**: The problem is scientifically grounded. It uses the standard Michaelis–Menten model for enzyme kinetics to describe neurotransmitter uptake by a transporter, a common and valid approach in neuropharmacology. The effect of a competitive inhibitor on the apparent Michaelis constant ($K_m^{\\text{app}}$) while leaving the maximal velocity ($V_{\\max}$) unchanged is a fundamental concept in biochemistry. The parameter values, while simplified for a problem, are physiologically plausible.\n2.  **Non-Formalizable or Irrelevant**: The problem is formalizable into a set of algebraic equations. It is directly relevant to the topic of pharmacotherapy for ADHD, as it models the mechanism of action of stimulant medications like methylphenidate.\n3.  **Incomplete or Contradictory Setup**: The problem is fully specified. It provides all necessary parameters, equations, and conditions to determine the final state from the initial state and thus compute the required change. There are no contradictions in the given information.\n4.  **Unrealistic or Infeasible**: The setup is a standard, albeit simplified, model of in vivo neurochemical dynamics and is not unrealistic or infeasible.\n5.  **Ill-Posed or Poorly Structured**: The problem is well-posed. The structure is logical and leads to a unique, stable solution. The terms used are standard and unambiguous in the context of enzyme kinetics.\n6.  **Pseudo-Profound, Trivial, or Tautological**: While the problem is designed to have a clean solution, it is not trivial. It requires a correct application of the steady-state principle and Michaelis-Menten kinetics in two different conditions, and the algebraic manipulation to find the solution.\n7.  **Outside Scientific Verifiability**: The problem is a mathematical exercise based on established scientific models and is fully verifiable through calculation.\n\n### Step 3: Verdict and Action\nThe problem is **valid** as it is scientifically grounded, well-posed, and contains sufficient information for a unique solution. I will proceed with the solution.\n\nThe core of the problem lies in the steady-state condition where the rate of dopamine release, $R$, is exactly balanced by the rate of dopamine uptake, $v$. This relationship holds both before and after the administration of the competitive inhibitor.\n\nLet $[D]_0$ be the extracellular dopamine concentration at the initial steady state (before the drug) and $[D]_1$ be the concentration at the new steady state (after the drug).\n\nThe uptake rate before the inhibitor is given by:\n$$\nv_0 = \\frac{V_{\\max} [D]_0}{K_m + [D]_0}\n$$\nAt steady state, the release rate $R$ must equal this uptake rate:\n$$\nR = v_0 = \\frac{V_{\\max} [D]_0}{K_m + [D]_0} \\quad (1)\n$$\n\nAfter the administration of the competitive inhibitor, a new steady state is reached. The problem states that the inhibitor doubles the apparent Michaelis constant, so $K_m^{\\text{app}} = 2K_m$, while $V_{\\max}$ and the release rate $R$ remain unchanged.\n\nThe uptake rate at the new steady state is:\n$$\nv_1 = \\frac{V_{\\max} [D]_1}{K_m^{\\text{app}} + [D]_1} = \\frac{V_{\\max} [D]_1}{2K_m + [D]_1}\n$$\nAt this new steady state, the release rate $R$ is again equal to the new uptake rate $v_1$:\n$$\nR = v_1 = \\frac{V_{\\max} [D]_1}{2K_m + [D]_1} \\quad (2)\n$$\n\nSince the tonic release rate $R$ is assumed to be constant, we can equate the expressions for $R$ from equation $(1)$ and equation $(2)$:\n$$\n\\frac{V_{\\max} [D]_0}{K_m + [D]_0} = \\frac{V_{\\max} [D]_1}{2K_m + [D]_1}\n$$\n\nThe term $V_{\\max}$ is non-zero and appears on both sides of the equation, so it can be canceled out:\n$$\n\\frac{[D]_0}{K_m + [D]_0} = \\frac{[D]_1}{2K_m + [D]_1}\n$$\n\nWe now solve this equation for $[D]_1$. We can cross-multiply to get:\n$$\n[D]_0 (2K_m + [D]_1) = [D]_1 (K_m + [D]_0)\n$$\nExpanding both sides gives:\n$$\n2K_m [D]_0 + [D]_0 [D]_1 = K_m [D]_1 + [D]_1 [D]_0\n$$\nThe term $[D]_0 [D]_1$ appears on both sides and can be subtracted, simplifying the equation to:\n$$\n2K_m [D]_0 = K_m [D]_1\n$$\nSince $K_m = 200$ nM is a non-zero constant, we can divide both sides by $K_m$:\n$$\n2 [D]_0 = [D]_1\n$$\nThis elegant result shows that under the specified conditions, the new steady-state dopamine concentration $[D]_1$ is exactly double the initial concentration $[D]_0$. This derivation holds true regardless of the specific numerical values of $V_{\\max}$ and $K_m$, as long as the problem's conditions ($K_m^{\\text{app}} = 2K_m$, and constant $R$ and $V_{\\max}$) are met.\n\nThe problem asks for the change in extracellular dopamine concentration, $\\Delta [D]$, which is defined as:\n$$\n\\Delta [D] = [D]_1 - [D]_0\n$$\nSubstituting our derived relationship $[D]_1 = 2[D]_0$ into this definition:\n$$\n\\Delta [D] = 2[D]_0 - [D]_0 = [D]_0\n$$\nSo, the change in concentration is simply equal to the initial concentration.\n\nWe are given the initial concentration $[D]_0 = 40$ nM. Therefore:\n$$\n\\Delta [D] = 40 \\, \\text{nM}\n$$\nThe problem requires the answer to be rounded to four significant figures. To express $40$ with four significant figures, we write it as $40.00$.", "answer": "$$\n\\boxed{40.00}\n$$", "id": "4739184"}, {"introduction": "Effective clinical practice requires understanding not just how a drug works, but why its effects can vary so dramatically among individuals. This practice explores the critical role of pharmacogenomics in ADHD treatment, focusing on how genetic variations in drug-metabolizing enzymes alter patient outcomes. Using the non-stimulant atomoxetine as a model, you will calculate the impact of Cytochrome P450 2D6 (CYP2D6) \"poor metabolizer\" status on drug exposure. This exercise highlights the inverse relationship between drug clearance and steady-state concentration ($C_{ss,avg}$), demonstrating the scientific basis for personalized dosing strategies [@problem_id:4739211].", "problem": "A 28-year-old patient with attention-deficit/hyperactivity disorder (ADHD) is started on atomoxetine, a selective norepinephrine reuptake inhibitor used in ADHD pharmacotherapy. Atomoxetine is primarily metabolized by Cytochrome P450 2D6 (CYP2D6). Consider the following scientifically grounded assumptions for this scenario: linear, time-invariant pharmacokinetics; identical oral bioavailability, absorption kinetics, dosing interval, and volume of distribution across genotypes; and that steady-state has been achieved under a fixed oral dosing regimen.\n\nIn a Cytochrome P450 2D6 (CYP2D6) extensive metabolizer, the measured average steady-state plasma concentration over one dosing interval is $210$ ng/mL on a stable regimen. In a CYP2D6 poor metabolizer, the apparent oral clearance is reduced threefold relative to the extensive metabolizer, with all other parameters unchanged.\n\nUsing core pharmacokinetic definitions of steady-state exposure (e.g., average steady-state concentration defined by the ratio of exposure over the dosing interval to the interval length), compute the expected average steady-state concentration in the CYP2D6 poor metabolizer on the same dosing regimen. Express your final answer in ng/mL and round to three significant figures.", "solution": "The problem statement will be validated according to the specified criteria.\n\n### Step 1: Extract Givens\n- **Patient**: $28$-year-old with attention-deficit/hyperactivity disorder (ADHD).\n- **Drug**: Atomoxetine, a selective norepinephrine reuptake inhibitor.\n- **Metabolism**: Primarily by Cytochrome P450 2D6 (CYP2D6).\n- **Pharmacokinetic Assumptions**:\n    - Linear, time-invariant pharmacokinetics.\n    - Steady-state has been achieved under a fixed oral dosing regimen.\n    - Oral bioavailability ($F$), absorption kinetics ($k_a$), dosing interval ($\\tau$), and volume of distribution ($V_d$) are identical across genotypes.\n- **CYP2D6 Extensive Metabolizer (EM) Data**:\n    - Average steady-state plasma concentration ($C_{ss,avg,EM}$) is $210$ ng/mL.\n- **CYP2D6 Poor Metabolizer (PM) Data**:\n    - Apparent oral clearance ($CL_{oral,PM}$) is reduced threefold relative to the extensive metabolizer ($CL_{oral,EM}$).\n    - All other parameters are unchanged.\n- **Task**:\n    - Compute the expected average steady-state concentration in the CYP2D6 poor metabolizer ($C_{ss,avg,PM}$).\n    - Express the final answer in ng/mL, rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is subjected to a rigorous validation process.\n\n- **Scientifically Grounded (Critical)**: The problem is scientifically sound. It is based on fundamental, well-established principles of pharmacokinetics, specifically the relationship between drug clearance, dosing regimen, and steady-state concentration. The example of atomoxetine metabolism by CYP2D6 and the impact of its genetic polymorphism (Extensive vs. Poor Metabolizers) is a medically and scientifically accurate scenario in clinical pharmacology.\n- **Well-Posed**: The problem is well-posed. It provides sufficient information to determine a unique solution. The relationship between the key variables ($C_{ss,avg}$ and $CL_{oral}$) is clearly defined, and the relative change in clearance between the two genotypes allows for the calculation of the new steady-state concentration without needing a specific dose or absolute clearance values.\n- **Objective (Critical)**: The problem is stated in precise, quantitative, and unbiased language. It is free from subjective claims.\n- **Additional Checks**:\n    - **Scientific or Factual Unsoundness**: The premises are factually correct within the context of pharmacokinetics and pharmacogenomics. No violations of scientific principles are present.\n    - **Non-Formalizable or Irrelevant**: The problem is directly formalizable using standard pharmacokinetic equations. It is highly relevant to the stated topic—*pharmacotherapy for attention-deficit/hyperactivity disorder* within the field of *psychiatry*—as it models a critical aspect of personalizing atomoxetine treatment.\n    - **Incomplete or Contradictory Setup**: The setup is complete and self-consistent. The assumptions provided (e.g., same dosing regimen, linear PK) are necessary and sufficient for a clear solution.\n    - **Unrealistic or Infeasible**: The posited threefold reduction in clearance for a CYP2D6 poor metabolizer is a realistic magnitude observed in clinical practice for substrates of this enzyme.\n    - **Ill-Posed or Poorly Structured**: The problem is well-structured and leads to a single, meaningful solution.\n    - **Pseudo-Profound, Trivial, or Tautological**: The problem requires a correct application of core pharmacokinetic theory and is not trivial.\n    - **Outside Scientific Verifiability**: The principles and the outcome are scientifically verifiable.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. It is scientifically grounded, well-posed, objective, and relates directly to established pharmacokinetic principles. A complete solution will be provided.\n\n### Solution\nThe core principle governing this problem is the definition of average plasma concentration at steady-state ($C_{ss,avg}$) for a drug administered orally. At steady-state, the rate of drug administration is equal to the rate of drug elimination. For a fixed oral dosing regimen with dose $D$ administered over a dosing interval $\\tau$, the rate of drug administration is $\\frac{D}{\\tau}$. The rate of drug elimination is given by the product of the drug's apparent oral clearance ($CL_{oral}$) and its average steady-state concentration ($C_{ss,avg}$).\n\nTherefore, the fundamental relationship is:\n$$\n\\text{Rate of Administration} = \\text{Rate of Elimination}\n$$\n$$\n\\frac{D}{ \\tau} = CL_{oral} \\cdot C_{ss,avg}\n$$\nRearranging this equation to solve for the average steady-state concentration gives:\n$$\nC_{ss,avg} = \\frac{D}{CL_{oral} \\cdot \\tau}\n$$\nThis relationship shows that for a constant dosing regimen ($D$ and $\\tau$ are fixed), the average steady-state concentration is inversely proportional to the apparent oral clearance:\n$$\nC_{ss,avg} \\propto \\frac{1}{CL_{oral}}\n$$\nWe can now apply this principle to the two genotypes described: the Extensive Metabolizer (EM) and the Poor Metabolizer (PM). Let us denote their respective average steady-state concentrations as $C_{ss,avg,EM}$ and $C_{ss,avg,PM}$, and their apparent oral clearances as $CL_{oral,EM}$ and $CL_{oral,PM}$.\n\nAccording to the derived relationship, we can write:\n$$\nC_{ss,avg,EM} = \\frac{D}{CL_{oral,EM} \\cdot \\tau}\n$$\n$$\nC_{ss,avg,PM} = \\frac{D}{CL_{oral,PM} \\cdot \\tau}\n$$\nThe problem states that the dosing regimen ($D$ and $\\tau$) is the same for both genotypes. To find the relationship between their concentrations, we can take the ratio of the two equations:\n$$\n\\frac{C_{ss,avg,PM}}{C_{ss,avg,EM}} = \\frac{\\frac{D}{CL_{oral,PM} \\cdot \\tau}}{\\frac{D}{CL_{oral,EM} \\cdot \\tau}}\n$$\nThe terms for dose ($D$) and dosing interval ($\\tau$) cancel out, simplifying the expression to:\n$$\n\\frac{C_{ss,avg,PM}}{C_{ss,avg,EM}} = \\frac{CL_{oral,EM}}{CL_{oral,PM}}\n$$\nThe problem provides the relationship between the clearances: the apparent oral clearance in a poor metabolizer is reduced threefold relative to the extensive metabolizer. This is expressed mathematically as:\n$$\nCL_{oral,PM} = \\frac{1}{3} CL_{oral,EM}\n$$\nSubstituting this into our ratio equation:\n$$\n\\frac{C_{ss,avg,PM}}{C_{ss,avg,EM}} = \\frac{CL_{oral,EM}}{\\frac{1}{3} CL_{oral,EM}} = 3\n$$\nThis result shows that the average steady-state concentration in the poor metabolizer is expected to be three times higher than in the extensive metabolizer. We can now solve for $C_{ss,avg,PM}$:\n$$\nC_{ss,avg,PM} = 3 \\cdot C_{ss,avg,EM}\n$$\nThe problem provides the value for the extensive metabolizer: $C_{ss,avg,EM} = 210 \\, \\text{ng/mL}$.\nSubstituting this value:\n$$\nC_{ss,avg,PM} = 3 \\cdot 210 \\, \\text{ng/mL} = 630 \\, \\text{ng/mL}\n$$\nThe problem requires the answer to be rounded to three significant figures. The calculated value is exactly $630$. To unambiguously represent this with three significant figures, we write it in scientific notation as $6.30 \\times 10^2$.", "answer": "$$\\boxed{6.30 \\times 10^2}$$", "id": "4739211"}, {"introduction": "The ultimate goal of clinical science is to inform decision-making in the face of uncertainty. This final practice moves from individual physiology to population-level evidence, teaching you how to synthesize data from a randomized controlled trial (RCT) to guide treatment choices. You will calculate the Number Needed to Treat (NNT) and Number Needed to Harm (NNH), two of the most powerful metrics in evidence-based medicine. Furthermore, you will engage with a decision-analytic model to determine a rational threshold for balancing clinical benefits against potential harms, a skill essential for navigating the complex trade-offs inherent in modern pharmacotherapy [@problem_id:4739165].", "problem": "A randomized controlled trial (RCT) compared a long-acting stimulant to atomoxetine for the pharmacotherapy of Attention-Deficit/Hyperactivity Disorder (ADHD). The trial enrolled two parallel arms of equal size and followed participants for $12$ weeks. Response was defined a priori as achieving at least a $30\\%$ reduction from baseline on a validated ADHD symptom scale and being rated as “much improved” or “very much improved” on the Clinical Global Impressions–Improvement scale. Safety was monitored and “harm” was operationalized as discontinuation due to adverse events. In the stimulant arm, $240$ of $400$ participants met the response criterion by week $12$, and $40$ of $400$ discontinued due to adverse events. In the atomoxetine arm, $190$ of $400$ met the response criterion by week $12$, and $22$ of $400$ discontinued due to adverse events.\n\nStarting from the foundational definitions of event probability and risk difference in trial arms, construct the Number Needed to Treat (NNT) and the Number Needed to Harm (NNH) for the stimulant relative to atomoxetine over the $12$-week horizon. Then, formalize a population-level net clinical utility model in which each additional responder contributes utility $u_{b}=1$ (one responder-equivalent) and each discontinuation due to adverse events contributes disutility $u_{h}=w$ responder-equivalents, with $w>0$ reflecting the decision-maker’s trade-off weight. Using this model, derive the threshold value $w^{*}$ at which the expected population-level net benefit of choosing the stimulant over atomoxetine is exactly zero.\n\nRound your final reported value for $w^{*}$ to four significant figures. Report $w^{*}$ as a dimensionless quantity. Do not include units in your final answer.", "solution": "The problem is first subjected to a validation process.\n\n### Step 1: Extract Givens\n- Trial design: Randomized controlled trial (RCT), two parallel arms of equal size.\n- Follow-up duration: $12$ weeks.\n- Treatment arms: Long-acting stimulant (S) and atomoxetine (A).\n- Response definition: $\\geq 30\\%$ reduction from baseline on a validated ADHD symptom scale AND rated as “much improved” or “very much improved” on the Clinical Global Impressions–Improvement scale.\n- Harm definition: Discontinuation due to adverse events.\n- Sample sizes: $n_S = 400$ for the stimulant arm, $n_A = 400$ for the atomoxetine arm.\n- Stimulant arm outcomes: $r_S = 240$ participants met the response criterion; $h_S = 40$ participants discontinued due to adverse events.\n- Atomoxetine arm outcomes: $r_A = 190$ participants met the response criterion; $h_A = 22$ participants discontinued due to adverse events.\n- Utility model parameters:\n  - Utility of one additional responder: $u_b = 1$ responder-equivalent.\n  - Disutility of one discontinuation due to adverse events: $u_h = w$ responder-equivalents, where $w > 0$.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded (Critical)**: The problem is grounded in the established principles of clinical trial analysis, biostatistics, and health economics (decision analysis). The use of Number Needed to Treat (NNT), Number Needed to Harm (NNH), and utility-based models are standard methodologies in evidence-based medicine. The data and context are scientifically realistic for a large-scale RCT in psychiatry.\n- **Well-Posed**: The problem is well-posed. It provides all necessary data to calculate the requested quantities. The objectives are clearly defined: calculate NNT and NNH, and then derive a specific threshold value $w^*$ from a given utility model. The model is structured to yield a unique solution.\n- **Objective (Critical)**: The problem is stated in precise, objective language. It uses formal definitions for response and harm, and provides quantitative data from a hypothetical RCT. There are no subjective or opinion-based statements.\n\nThe problem does not exhibit any flaws. It is scientifically sound, well-posed, objective, and contains a complete and consistent setup.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid and a full solution will be provided.\n\n### Solution Derivation\n\nThe solution begins by defining the probabilities of the beneficial and harmful outcomes for each treatment arm, based on the provided trial data.\n\nLet $S$ denote the stimulant arm and $A$ denote the atomoxetine arm.\nLet $R$ be the event of a participant meeting the response criterion (benefit).\nLet $H$ be the event of a participant discontinuing due to adverse events (harm).\n\nThe probabilities of response for each arm are estimated from the sample data:\nThe probability of response in the stimulant arm is:\n$$p_R(S) = \\frac{\\text{number of responders in S}}{\\text{total participants in S}} = \\frac{r_S}{n_S} = \\frac{240}{400} = 0.6$$\nThe probability of response in the atomoxetine arm is:\n$$p_R(A) = \\frac{\\text{number of responders in A}}{\\text{total participants in A}} = \\frac{r_A}{n_A} = \\frac{190}{400} = 0.475$$\n\nThe probabilities of harm for each arm are:\nThe probability of harm in the stimulant arm is:\n$$p_H(S) = \\frac{\\text{number of harms in S}}{\\text{total participants in S}} = \\frac{h_S}{n_S} = \\frac{40}{400} = 0.1$$\nThe probability of harm in the atomoxetine arm is:\n$$p_H(A) = \\frac{\\text{number of harms in A}}{\\text{total participants in A}} = \\frac{h_A}{n_A} = \\frac{22}{400} = 0.055$$\n\nThe Number Needed to Treat (NNT) is the reciprocal of the Absolute Risk Reduction (ARR). The ARR represents the increase in the probability of a beneficial outcome (response) when using the stimulant compared to atomoxetine.\n$$ARR = p_R(S) - p_R(A) = 0.6 - 0.475 = 0.125$$\nTherefore, the NNT is:\n$$NNT = \\frac{1}{ARR} = \\frac{1}{0.125} = 8$$\nThis means one must treat $8$ patients with the stimulant instead of atomoxetine to achieve one additional response.\n\nThe Number Needed to Harm (NNH) is the reciprocal of the Absolute Risk Increase (ARI). The ARI represents the increase in the probability of a harmful outcome (discontinuation) when using the stimulant compared to atomoxetine.\n$$ARI = p_H(S) - p_H(A) = 0.1 - 0.055 = 0.045$$\nTherefore, the NNH is:\n$$NNH = \\frac{1}{ARI} = \\frac{1}{0.045} = \\frac{1}{45/1000} = \\frac{1000}{45} = \\frac{200}{9} \\approx 22.22$$\nThis means for every $22$ to $23$ patients treated with the stimulant instead of atomoxetine, one additional patient will discontinue due to an adverse event.\n\nNext, we formalize the net clinical utility model. The utility is expressed in \"responder-equivalents\". The benefit of a response is $u_b = 1$. The disutility (cost) of a harm event is $u_h = w$. The expected net utility for a single patient in a given arm is the expected benefit minus the expected harm.\n\nExpected net utility for a patient in the stimulant arm ($U_S$):\n$$U_S = p_R(S) \\cdot u_b - p_H(S) \\cdot u_h = p_R(S) - w \\cdot p_H(S)$$\nExpected net utility for a patient in the atomoxetine arm ($U_A$):\n$$U_A = p_R(A) \\cdot u_b - p_H(A) \\cdot u_h = p_R(A) - w \\cdot p_H(A)$$\n\nThe expected population-level net benefit of choosing the stimulant over atomoxetine is proportional to the difference in per-patient expected utilities, $\\Delta U = U_S - U_A$. We are looking for the threshold value of the weight, $w^*$, where this net benefit is exactly zero.\n$$\\Delta U = 0$$\n$$(p_R(S) - w^* \\cdot p_H(S)) - (p_R(A) - w^* \\cdot p_H(A)) = 0$$\nRearranging the terms:\n$$(p_R(S) - p_R(A)) - w^* \\cdot (p_H(S) - p_H(A)) = 0$$\nThis equation can be expressed in terms of ARR and ARI:\n$$ARR - w^* \\cdot ARI = 0$$\nSolving for $w^*$:\n$$w^* = \\frac{ARR}{ARI}$$\nThis result shows that the threshold weight $w^*$ is the ratio of the absolute benefit gain to the absolute harm increase. It is also equivalent to the ratio of NNH to NNT.\n$$w^* = \\frac{1/NNT}{1/NNH} = \\frac{NNH}{NTT}$$\n\nSubstituting the calculated values for ARR and ARI:\n$$w^* = \\frac{0.125}{0.045} = \\frac{125}{45} = \\frac{25 \\cdot 5}{9 \\cdot 5} = \\frac{25}{9}$$\nAs a decimal, this is:\n$$w^* = 2.7777...$$\nThe problem requires rounding the final value to four significant figures.\n$$w^* \\approx 2.778$$\nThis dimensionless quantity $w^*$ represents the indifference point. If a decision-maker considers one harm event (discontinuation) to be as detrimental as failing to achieve $2.778$ responses, they would be indifferent between the two treatments.", "answer": "$$\\boxed{2.778}$$", "id": "4739165"}]}